PHARMACEUTICAL
Dry Eye
Recent Scientific Publications on Dry Eye
WHITE PAPER
Evolution of Systane® Artificial Tears
WHITE PAPER
Thermal Pulsation Systems and Topical Immunomodulators for Managing Meibomian Gland Dysfunction
CLINICAL SCIENCE COMPENDIA
Systane iLux Clinical Science Compendium
PERSPECTIVES ON VISION
Preoperative Dry Eye Management with Systane iLux2
WHITE PAPER
Scientific Overview of Ocular Lubricants in the United States
WHITE PAPER
SYSTANE® HYDRATION PF's Dual-Polymer Technology: Hydroxypropyl-Guar and Sodium Hyaluronate
EYSUVIS® is the first and only FDA-approved corticosteroid for short-term dry eye treatment.
IMPORTANT SAFETY INFORMATION
EYSUVIS® should not be used if you have a viral infection in your eye. Talk to your doctor before using EYSUVIS® if you think you may have a viral, bacterial, or fungal eye infection.
Your doctor should examine your eyes before prescribing EYSUVIS®, to check for increased eye pressure or damage to the surface of the eye.
Consult your doctor if pain, redness, itching, or inflammation develops or gets worse. Wash your hands well before each use.
Do not allow the dropper tip to touch any surface, as this may contaminate the suspension. Shake the bottle for two to three seconds before using. If a dose is missed, take the missed dose when remembered.
Remove contact lenses before using EYSUVIS®; they may be reinserted 15 minutes later. The most common adverse drug reaction following the use of EYSUVIS® for two weeks was instillation site pain, which was reported in 5% of patients.